enGene Therapeutics Inc. (ENGN) stock analysis
Close on Nov 11, 2026Market cap $120.63MP/E –Yield 0.00%
StockData Score
Prices as of Nov 11, 2026How the score works
Weak3 of 30 checks passed
enGene Therapeutics passes 3 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 0/6
- Past performance
- 0/6
- Financial health
- 2/6
- Dividend
- 0/6
What stands out
Low debt
Debt is 10.9% of shareholders' equity, under the 40% we consider low.
P/B below the industry
enGene Therapeutics's price-to-book of 0.52 is below the Drugs median of 2.29.
Short-term assets cover short-term debts
Current assets are 10.21 times current liabilities.
What to watch
Return on capital under 10%
Return on invested capital was -3862%, below the 10% that usually covers the cost of capital.
EPS growing under 10% a year
Diluted EPS grew -62.7% a year over the last three fiscal years.
Interest not well covered
Operating income covers interest expense -44.5 times; we look for at least 5.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -411% of total debt; we look for at least 20%.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
enGene Therapeutics's price-to-book of 0.52 is below the Drugs median of 2.29.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growing under 10% a year
Diluted EPS grew -62.7% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on capital under 10%
Return on invested capital was -3862%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
enGene Therapeutics's return on equity of -60.5% is below the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health2/6
Low debt
Debt is 10.9% of shareholders' equity, under the 40% we consider low.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -411% of total debt; we look for at least 20%.
Interest not well covered
Operating income covers interest expense -44.5 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 10.21 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -1.53; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
enGene Therapeutics has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for enGene Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 1.4
- Drugs median 2.3
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $1.56M
- Value traded per 1% price move
- $416.51K
Downside
High risk
- Typical loss in a bad month
- 80.2%
- Volatility (annualized)
- 118%
- Sharpe ratio, 1 year
- -0.63
- Beta to the S&P 500 (5Y)
- -0.50
Typical bad-month loss, week by week
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| EPS, diluted | +56.8% | -62.7% | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -53.3% | |
| Return on assets | – | – | -44.0% | |
| Current ratio | – | – | 6.30 | |
| Debt to equity | – | – | 0.09 | |
| Net debt to EBITDA | – | – | 0.28× | |
| Interest coverage | – | – | -41.1× | |
| Diluted shares | – | – | 51M |
Cash use needs five years of cash flow figures
enGene Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$117.30M
- Cash generatingOperating cash flow above zero-$99.24M
- Return on assets improvedROA up on the prior year-63.4% → -37.7%
- Earnings backed by cashOperating cash flow above net income-$99.24M vs -$117.30M
- Less leverageLong-term debt to assets fell7.2% → 6.9%
- Better liquidityCurrent ratio rose16.87 → 6.30
- No dilutionShare count did not rise38M → 51M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –
See a number that looks wrong?